YOUR BUSINESS AUTHORITY

Springfield, MO

Log in Subscribe

Roche to buy Spark Therapeutics for $4.8B

Posted online

Swiss drugmaker Roche agreed to buy Philadelphia-based Spark Therapeutics for $4.8 billion.

Spark, which creates gene therapies for genetic diseases, is behind the blindness treatment called Luxturna, which costs $425,000 per eye.

"Spark Therapeutics' proven expertise in the entire gene therapy value chain may offer important new opportunities for the treatment of serious diseases," Roche CEO Severin Schwan said in a news release. "Spark Therapeutics' haemophilia A programme could become a new therapeutic option for people living with this disease."

Read more from Business Insider.

Comments

No comments on this story |
Please log in to add your comment
Editors' Pick
Letter to the Editor: No half-baked cake for our kids. No half-baked school grades, either.

Nixa Superintendent Gearl Loden weighs in on A-F grade cards.

Most Read
Update cookies preferences